Formulary Search Results for: CALCIUM AND VITAMIN D
2.8.4 Reversal of anticoagulation - View Category
Restrictions:
Restricted to use only on the advice of a Consultant Haematologist for the reversal of anticoagulation in adults treated with a direct factor Xa inhibitor where there is life-threatening or uncontrolled bleeding. In addition, use should be in accordance with the local protocol (in development).
2.9 Antiplatelet drugs - View Category
Restrictions:
Restricted to use in accordance with the NHSGGC Guidelines for the Secondary Prevention of Stroke and TIA
9.1.8 Drugs for other blood disorders - View Category
Restrictions:
Restricted to specialist use for the treatment of severe and moderately severe haemophilia B (congenital factor IX deficiency) in adult patients without a history of factor IX inhibitors.
3.4.2 Allergen Immunotherapy - View Category
Restrictions:
Restricted to specialist use for patients with severe asthma with type 2 inflammation and blood eosinophils ≥150 cells/microlitre and FeNO ≥25 parts per billion, and ≥4 exacerbations in the 12 months prior to initiating biologic treatment (anti-IgE or anti-IL-5 therapies) and who still experience ≥2 exacerbations per year despite this biologic treatment.
Prescribing Notes:
The following indication is not recommended by SMC and is non-Formulary:
- In adults as add-on maintenance treatment for uncontrolled chronic obstructive pulmonary disease (COPD) characterised by raised blood eosinophils on a combination of an inhaled corticosteroid (ICS), a long-acting beta2-agonist (LABA), and a long-acting muscarinic antagonist (LAMA), or on a combination of a LABA and a LAMA if ICS is not appropriate.
5.3.3 Viral hepatitis - View Category
Restrictions:
Restricted to initiation by, or on the advice of, a specialist treating hepatitis B in accordance with local protocol.
Prescribing Notes:
Tenofovir for the treatment of hepatitis B is subject to an agreed Shared Care Protocol which allows the ongoing prescribing to be carried out by the patient's GP under guidance and review by the acute specialist.
To access this Shared Care Agreement, and others, click here
2.8.1 Parenteral anticoagulants - View Category
Restrictions:
Restricted to specialist initiation only. The treatment and prevention of VTE in patients with solid tumours use is restricted to initiation by healthcare professionals experienced in the treatment of VTE and use according to local protocol.
Prescribing Notes:
When dalteparin is used in the extended treatment of VTE and prevention of recurrence in patients with solid tumours, prescribers are reminded that a dose reduction is required following the first month of treatment, and where there is a transfer of care, the need for this dose reduction should be communicated clearly. For further dosing information, see the product literature or BNF.
4.2.2 Antipsychotic depot injections - View Category
Restrictions:
Restricted to specialist initiation only.
Prescribing Notes:
For further information, see the NHSGGC depot (LAI) algorithm.
4.2.2 Antipsychotic depot injections - View Category
Restrictions:
Restricted to specialist initiation only.
Prescribing Notes:
For further information, see the NHSGGC depot (LAI) algorithm.
4.2.2 Antipsychotic depot injections - View Category
Restrictions:
Restricted to specialist initiation only.
Prescribing Notes:
For further information, see the NHSGGC depot (LAI) algorithm.
4.4 CNS stimulants and drugs used for attention deficit hyperactivity disorder - View Category
Restrictions:
Restricted to second line therapy for the treatment of ADHD and initiation by child or adolescent psychiatrists or paediatricians with expertise in ADHD.